SecBot SecBot
6-K ·Filed Jun 8, 2026

SCNI

Scinai Immunotherapeutics Ltd.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001213900-26-066166
Notable filing: 6-K
Actionable Insight • Neutral

This filing is purely administrative and has no trading implications. Monitor the June 16 shareholder meeting for approval of Proposal No. 6 and any subsequent material updates on the company's CDMO transition or funding status.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
SCNI ▼ -42.59% at T+60d
NEUTRAL call -42.59% · α vs SPY -46.10% · entry $0.4076 → $0.2340
Entry = T+0 close
Jun 8, 2026
via day close
T+1d
-13.08%
call -13.08% · α -12.78%
$0.3543
settled 5mo ago
T+5d
-10.60%
call -10.60% · α -12.71%
$0.3644
settled 4mo ago
T+20d
-33.76%
call -33.76% · α -34.59%
$0.2700
settled 4mo ago
T+60d
-42.59%
call -42.59% · α -46.10%
$0.2340
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Scinai filed a 6-K correcting a clerical error in its May 12 proxy statement regarding Chairman Mark Germain's service agreement term. The correction clarifies that his director term runs until the second annual meeting after the June 16, 2026 meeting, not the second anniversary of the meeting. This is a routine administrative correction with no material financial or operational impact.

Key Facts

  • Filing corrects an inadvertent error in the May 12, 2026 proxy statement for the June 16, 2026 Annual General Meeting.
  • Proposal No. 6 extends Chairman Mark Germain's Services Agreement; the correction clarifies his director term expires at the second annual meeting after the 2026 meeting, not the second anniversary.
  • No financial figures, business updates, or changes to operations are disclosed in this filing.

Financial Impact

No financial impact; administrative correction only.

Risk Factors

  • No new risks introduced; existing going-concern and delisting risks from prior filings remain unchanged.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-066166
Document: 0001213900-26-066166-index-headers.html0001213900-26-066166
Document: 0001213900-26-066166-index.html0001213900-26-066166
Document: 0001213900-26-066166.txt0001213900-26-066166
16 reports for SCNI
Performance horizon
100% Hit rate @ T+60 5 of 5 directional calls Went positive at some point 11 of 12 best @ T+60▲ +57.90%Apr 1, 2026
Filters
Rows
Reports for SCNI — sortable, filterable
TypeNow
Oct 20, 2026
7d ago
6-K
NEUTRAL ★ 4/10
$0.6813awaiting T+60—$0.5301 (−22.19%)
Oct 16, 2026
11d ago
6-K
BEARISH ★ 6/10
$0.7520awaiting T+60—$0.5301 (+29.51%)
Oct 16, 2026
11d ago
Press Release
BEARISH ★ 5/10
$0.7524awaiting T+60—$0.5301 (+29.55%)
Oct 15, 2026
12d ago
6-K
BEARISH ★ 6/10
$0.9015awaiting T+60—$0.5301 (+41.20%)
Oct 13, 2026
14d ago
6-K
BULLISH ★ 6/10
$1.23awaiting T+60—$0.5301 (−56.90%)
Oct 6, 2026
21d ago
EFFECT
BEARISH ★ 5/10
$1.22awaiting T+60—$0.5301 (+56.55%)
Sep 21, 2026
5w ago
6-K
NEUTRAL ★ 4/10
$1.69awaiting T+60—$0.5301 (−68.63%)
Aug 26, 2026
8w ago
6-K
BEARISH ★ 6/10
$2.87awaiting T+60—$0.5301 (+81.53%)
Aug 19, 2026
9w ago
6-K
BEARISH ★ 6/10
$0.2740awaiting T+60—$0.5301 (−93.47%)
Jun 17, 2026
18w ago
6-K
NEUTRAL ★ 2/10
$0.3370 $0.2440▼ −27.60%▼ −30.28%$0.5301 (+57.30%)
Showing 10 of 16

US Market Status

Market Open — Closes in 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026